We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · February 22, 2021

Role of Consolidation Durvalumab in EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
Brief Report: Role of Consolidation Durvalumab in Patients With EGFR and HER2 Mutant Unresectable Stage III NSCLC
J Thorac Oncol 2021 Feb 01;[EPub Ahead of Print], JA Hellyer, JV Aredo, M Das, K Ramchandran, SK Padda, JW Neal, HA Wakelee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.